Statin Wars: The Heavyweight Match-Atorvastatin versus Rosuvastatin for the Treatment of Atherosclerosis, Heart Failure, and Chronic Kidney Disease

References

• . Uzui H, Nakano A, Mitsuke Y, . Comparison of lipophilic and hydro-philic statins on atheroma stabilizing effects in hypercholesterolemic patients. Presented at: European Society of Cardiology Congress 2010. August 28-September 1, 2010;Stockholm, Sweden. Abstract P5565
   Google Scholar
• . Lavie CJ, Milani RV, O'Keefe JH. Does the choice of statin really matter? Postgrad Med. 2010;122(3):243–247
   PubMed Web of Science ®Google Scholar
• . Lavie CJ, Milani RV. High-dose atorvastatin in acute coronary and cerebrovascular syndromes. JACC Cardiovasc Interv. 2010;3(3):340–342
   PubMed Web of Science ®Google Scholar
• . Bybee KA, Lee JH, O'Keefe JH. Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. Curr Med Res Opin. 2008;24(4):1217–1229
   PubMed Web of Science ®Google Scholar
• . Nicholls SJ, Ballantyne CM, Barter PJ, . Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078–2087
   PubMed Web of Science ®Google Scholar
• . Lee CW, Kang SJ, Ahn JM, . Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial). Am J Cardiol. 2012;109(12):1700–1704
   PubMedGoogle Scholar
• . Hong YJ, Jeong MH, Hachinohe D, . Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Circ J. 2011;75(2):398–406
   PubMedGoogle Scholar
• . American Stroke Association; American Heart Association. Heart disease and stroke statistics—2005 update, http://my.clevelandclinic.org/Documents/heart/1105390918119HDSStats2005Update.pdf Accessed November 6, 2012
   Google Scholar
• . Bonow RO, Bennett S, Casey DE Jr, ; American College of Cardiology; American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures); Heart Failure Society of America. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America. J Am Coll Cardiol. 2005;46(6):1144–1178
   PubMed Web of Science ®Google Scholar
• . Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J. 1997;133(6):703–712
   PubMed Web of Science ®Google Scholar
• . Sola S, Mir MQ, Rajagopalan S, Helmy T, Tandon N, Khan BV. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail. 2005;11(8):607–612
   PubMedGoogle Scholar
• . Ray JG, Gong Y, Sykora K, Tu JV. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med. 2005;165(1):62–67
   PubMedGoogle Scholar
• . Foody JM, Shah R, Galusha D, Masoudi FA, Havranek EP, Krumholz HM. Statins and mortality among elderly patients hospitalized with heart failure. Circulation. 2006;113(8):1086–1092
   PubMedGoogle Scholar
• . Folkeringa RJ, Van Kraaij DJ, Tieleman RG, Nieman FH, Pinto YM, Crijns HJ. Statins associated with reduced mortality in patients admitted for congestive heart failure. J Card Fail. 2006;12(2):134–138
   PubMedGoogle Scholar
• . Milionis HJ, Rizos E, Kostapanos M, . Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin. 2006;22(6):1123–1131
   PubMed Web of Science ®Google Scholar
• . Leiter LA, Rosenson RS, Stein E, ; POLARIS study investigators. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis. 2007;194(2):e154–e164
   Google Scholar
• . Insull W Jr, Ghali JK, Hassman DR Y As JW, Gandhi SK, Miller E; SOLAR Study Group. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clin Proc. 2007;82(5):543–550
   PubMed Web of Science ®Google Scholar
• . Tavazzi L, Maggioni AP, Marchioli R, ; Gissi-HF Investigators.Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231–1239
   PubMed Web of Science ®Google Scholar
• . Kjekshus J, Apetrei E, Barrios V, ; CORONA Group.Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248–2261
   PubMed Web of Science ®Google Scholar
• . Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004;43(4):642–648
   PubMed Web of Science ®Google Scholar
• . Takagi H, Umemoto T. Atorvastatin, not rosuvastatin, improves cardiac function in heart failure: a meta-analysis of randomized trials. Int J Cardiol. 2012;155(2):296–299
   PubMedGoogle Scholar
• . Wannamethee SG, Welsh P, Lowe GD, . N-terminal pro-brain natriuretic peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease. J Am Coll Cardiol. 2011;58(1):56–64
   PubMedGoogle Scholar
• . Curtis JP, Sokol SI, Wang Y, . The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol. 2003;42(4):736–742
   PubMed Web of Science ®Google Scholar
• . Tsutamoto T, Sakai H, Ibe K, . Effect of atorvastatin vs. rosuvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathy. Circ J. 2011;75(9):2160–2166
   PubMedGoogle Scholar
• . Charach G, George J, Afek A, . Antibodies to oxidized LDL as predictors of morbidity and mortality in patients with chronic heart failure. J Card Fail. 2009;15(9):770–774
   PubMedGoogle Scholar
• . Brunner—La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J. 2001;22(13):1136–1143
   PubMedGoogle Scholar
• . Kasama S, Toyama T, Sumino H, . Prognostic value of cardiac sympathetic nerve activity evaluated by [123I]m-iodobenzylguanidine imaging in patients with ST-segment elevation myocardial infarction. Heart. 2011;97(1):20–26
   PubMedGoogle Scholar
• . Xu M, Yuan G, Wei F. Effect of atorvastatin in patients with chronic heart failure—insights from randomized clinical trials. Arch Med Sci. 2010;6(6):866–873
   PubMedGoogle Scholar
• . Khush KK, Waters DD, Bittner V, . Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation. 2007;115(5):576–583
   PubMed Web of Science ®Google Scholar
• . Lavie CJ, Mehra MR. Statins and advanced heart failure—alive but barely breathing after CORONA and GISSI-HE Congest Heart Fail. 2009;15(4):157–158
   PubMedGoogle Scholar
• . Ashton E, Windebank E, Skiba M, . Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. Int J Cardiol. 2011;146(3):404–407
   PubMedGoogle Scholar
• . Bianchi S, Bigazzi R, Caiazza A, Campese VM. Acontrolled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41(3):565–570
   PubMed Web of Science ®Google Scholar
• . Campese VM, Park J. HMG-CoA reductase inhibitors and the kidney. Kidney Int. 2007;71(12):1215–1222
   PubMedGoogle Scholar
• . O'Donnell MP, Kasiske BL, Kim Y, Schmitz PG, Keane WF. Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis. 1993;22(1):83–89
   PubMedGoogle Scholar
• . Yokota N, O'Donnell M, Daniels F, . Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. Am J Nephrol. 2003;23(1):13–17
   PubMedGoogle Scholar
• . Massy ZA, Kim Y, Guijarro C, , Kasiske BL, Keane WF, O'Donnell MP. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun. 2000;267(2):536–540
   PubMedGoogle Scholar
• . Joyce M, Kelly C, Winter D, Chen G, Leahy A, Bouchier—Hayes D. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. J Surg Res. 2001;101(1):79–84
   PubMedGoogle Scholar
• . Athyros VG, Mikhailidis DP, Papageorgiou AA, . The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GRE ACE) study. J Clin Pathol. 2004;57(7):728–734
   PubMed Web of Science ®Google Scholar
• . Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP; ALLIANCE Investigators. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis. 2009;53(5):741–750
   PubMed Web of Science ®Google Scholar
• . Koren MJ, Hunninghake DB; ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol. 2004;44(9):1772–1779
   PubMed Web of Science ®Google Scholar
• . Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17(7):2006–2016
   PubMed Web of Science ®Google Scholar
• . Shepherd J, Kastelein JJ, Bittner V, ; Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2(6):1131–1139
   PubMedGoogle Scholar
• . Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005–2016
   PubMed Web of Science ®Google Scholar
• . Keller DM. PLANET I and II: Atorvastatin beats rosuvastatin for protecting kidneys in diabetic and nondiabetic patients. http://www.theheart.org/article/1095269.do. Published July 5, 2010. Accessed July 25, 2012
   Google Scholar
• . Alsheikh—Ali AA, Ambrose MS, Kuvin JT, Karas RH. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation. 2005;111(23):3051–3057
   PubMed Web of Science ®Google Scholar
• . Wanner C, Krane V, März W, ; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–248
   PubMed Web of Science ®Google Scholar
• . März W, Genser B, Drechsler C, ; German Diabetes and Dialysis Study Investigators. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol. 2011;6(6):1316–1325
   PubMedGoogle Scholar
• . Fellström BC, Jardine AG, Schmieder RE, ; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407
   PubMed Web of Science ®Google Scholar
• . Holdaas H, Holme I, Schmieder RE, ; AURORA study group. Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol. 2011;22(7):1335–1341
   PubMed Web of Science ®Google Scholar
• . Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR; ASCOT Investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: 11x—year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J. 2011;32(20):2525–2532
   PubMed Web of Science ®Google Scholar
• . Ridker PM, Danielson E, Fonseca FA, ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207
   PubMed Web of Science ®Google Scholar
• . de Lorgeril M, Salen P, Abramson J, . Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med. 2010;170(12):1032–1036
   PubMedGoogle Scholar
• . Wiviott SD, de Lemos JA, Cannon CP, . A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation. 2006;113(11):1406–1414
   PubMedGoogle Scholar
• . Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs. 2010;10(1):11–28
   PubMed Web of Science ®Google Scholar
• . McAfee AT, Ming EE, Seeger JD, . The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf. 2006;15(7):444–453
   PubMedGoogle Scholar
• . Guthrie RM, Martin DR. The safety of rosuvastatin: effects on renal and hepatic function. Expert Opin Drug Saf. 2007;6(5):573–581
   PubMed Web of Science ®Google Scholar
• . García—Rodríguez LA, González—Pérez A, Stang MR, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiol Drug Saf. 2008;17(10):953–961
   PubMedGoogle Scholar